Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with iron deficiency anemia. A common side effect;Hipofosfatemia asociada a la administración intravenosa de hierro carboximaltosa en pacientes con anemia ferropénica. Un efecto secundario frecuente

Medicina Clinica

Volumn 145, Issue 3, 2015, Pages 108-111

  Sánchez González, Rebeca ^a   Ternavasio De La Vega, Hugo Guillermo ^a   Moralejo Alonso, Leticia ^a   Inés Revuelta, Sandra ^a   Fuertes Martín, Aurelio ^a  

^a Universidad de Salamanca   (Spain)

Author keywords

Ferric carboxymaltose; Hypophosphatemia; Iron deficiency anemia

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRITIN; PHOSPHATE; ANTIANEMIC AGENT; FERRIC ION; MALTOSE;

AGE; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE SEVERITY; FERRITIN BLOOD LEVEL; HUMAN; HYPOPHOSPHATEMIA; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; PHOSPHATE BLOOD LEVEL; RETROSPECTIVE STUDY; ADULT; AGED; ANALOGS AND DERIVATIVES; ANEMIA, IRON-DEFICIENCY; CHEMICALLY INDUCED; COMPLICATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; STATISTICAL MODEL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; FEMALE; FERRIC COMPOUNDS; HEMATINICS; HUMANS; HYPOPHOSPHATEMIA; INFUSIONS, INTRAVENOUS; LOGISTIC MODELS; MALE; MALTOSE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84937523776     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2014.10.016     Document Type: Article

References (9)

1. S.D. Anker, J. Comin Colet, G. Filippatos, R. Willenheimer, K. Dickstein, H. Drexler, and et al. Ferric carboxymaltose in patients with heart failure and iron deficiency N Engl J Med. 361 2009 2436 2448
2. C.F. Barish, T. Koch, A. Butcher, D. Morris, and D.B. Bregman Safety and efficacy of intravenous ferric carboxymaltose (750 mg) in the treatment of iron deficiency anemia: Two randomized, controlled trials Anemia. 2012 2012 1 9
3. I. Hussain, J. Bhoyroo, A. Butcher, T.A. Koch, A. He, and D.B. Bregman Direct comparison of the safety and efficacy of ferric carboxymaltose versus iron dextran in patients with iron deficiency anemia Anemia. 2013 2013 1 10
4. B.J. Schouten, P.J. Hunt, J.H. Livesey, C.M. Frampton, and S.G. Soule FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: A prospective study J Clin Endocrinol Metab. 94 2009 2332 2337
5. J.A. Barea Mendoza, I. Gredilla Zubiria, J. González Olmedo, and S. Mateo Alvarez Hipofosfatemia, una reacción adversa poco conocida del hierro intravenoso Med Clin (Barc). 143 2014 284 285
6. M.H. Seid, R.J. Derman, J.B. Baker, W. Banach, C. Goldberg, and R. Rogers Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: A randomized controlled clinical trial Am J Obstet Gynecol. 199 2008 435 e1 4357e
7. M. Prats, R. Font, C. Garcia, C. Cabre, M. Jariod, and A.M. Vea Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: Post-hoc analysis of a prospective study BMC Nephrol. 14 2013 167 174
8. M. Wolf, T.A. Koch, and D.B. Bregman Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women J Bone Miner Res. 28 2013 1793 1803
9. B.J. Schouten, M.P. Doogue, S.G. Soule, and P.J. Hunt Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia Ann Clin Biochem. 46 2009 16 7 169